Bachrodt Amy
Known title: SVP, FinanceCIK: 0002050422
Associated companies
Transaction History
| MAZE | ▲ Buy | Option Exercise | 2,500 | $26K | 4/1/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 2,200 | $65K | 4/1/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 300 | $9K | 4/1/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 5,000 | $52K | 3/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 1,300 | $58K | 3/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 3,700 | $168K | 3/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 4,064 | $187K | 2/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 736 | $34K | 2/2/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 4,844 | $50K | 2/2/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 156 | $2K | 2/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 200 | $9K | 2/2/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 2,497 | $26K | 1/22/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 2,503 | $26K | 1/22/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 5,000 | $228K | 1/22/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 4,796 | $50K | 1/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 2,405 | $93K | 1/2/2026 | View on chart |
| MAZE | ▼ Sell | Open Market | 2,595 | $103K | 1/2/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 204 | $2K | 1/2/2026 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 2,395 | $25K | 12/30/2025 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 2,605 | $27K | 12/30/2025 | View on chart |
| MAZE | ▼ Sell | Open Market | 5,000 | $200K | 12/30/2025 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 124 | $1K | 12/29/2025 | View on chart |
| MAZE | ▲ Buy | Option Exercise | 9,876 | $103K | 12/29/2025 | View on chart |
| MAZE | ▼ Sell | Open Market | 9,400 | $381K | 12/29/2025 | View on chart |
| MAZE | ▼ Sell | Open Market | 600 | $25K | 12/29/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pompe Disease Market Expected to Grow Through 2036
A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.
Pompe Disease Market Expected to Grow Through 2036. A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.